EGFR and non-small cell lung carcinoma: BACKGROUND: Research on the efficacy of first-line osimertinib in non-small cell lung cancer (NSCLC) patients with different epidermal growth factor receptor (EGFR) exon 19 deletion (19del) mutation sites is limited.